Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer

P He, L Ma, B Xu, Y Wang, X Li… - … Advances in Medical …, 2024 - journals.sagepub.com
In recent years, with the continuous development of molecular immunology, immune
checkpoint inhibitors (ICIs) have also been widely used in the treatment of gastric cancer …

Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors

A Adhikari, S Sapkota, S Gogia, KC Ojbindra - Cancer Epidemiology, 2024 - Elsevier
Background The advent of immune checkpoint inhibitors (ICI) has brought about a
significant transformation in the treatment of immunogenic tumors. On November 23, 2015 …

[HTML][HTML] Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical …

NP Nguyen, ME Chirila, BR Page… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
The standard of care for non-metastatic renal cancer is surgical resection followed by
adjuvant therapy for those at high risk for recurrences. However, for older patients, surgery …

Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma Metastases

APH Dove, A Wells, W Gong, D Liu… - American journal of …, 2022 - journals.lww.com
Objectives: The best fractionation for stereotactic body radiotherapy (SBRT) in renal cell
carcinoma (RCC) metastases has not been well defined. In addition, the literature on …

Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis

F **an, J Wu, L Zhong, G Xu - Medicine, 2023 - journals.lww.com
Background: The triple combination of programmed cell death 1 (PD1)/programmed cell
death ligand 1 (PDL1) inhibitors, radiotherapy (RT), and anti-angiogenesis agents has been …

Altered NCR3 Splice Variants May Result in Deficient NK Cell Function in Renal Cell Carcinoma Patients

X Wang, L Huang, X Wen, D Li, G Yang, J Zheng - in vivo, 2024 - iv.iiarjournals.org
Background/Aim: The natural killer (NK) cell function of patients with malignant tumours may
be suppressed by deficiency, and the poor prognosis of renal cell carcinoma (RCC) patients …

Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii

M Gaudreault, N Hardcastle, P Jackson… - International Journal of …, 2024 - Elsevier
Background Stereotactic ablative body radiotherapy (SABR) is a novel option to treat
primary renal cell carcinoma (RCC). However, a high radiation dose may be received by the …

Von Hippel-Lindau syndrome from the urologist and oncologist perspective—literature review

K Kowalik, P Narożnicki, K Hetman… - Oncology in Clinical …, 2024 - journals.viamedica.pl
Abstract Von Hippel-Lindau (VHL) syndrome is a rare genetic disorder characterized by
multiple retinal and cerebellar hemangioblastomas that tend to occur in a familial setting …

[PDF][PDF] MiR-15b-5p promotes growth and metastasis of renal clear cell carcinoma

X Bi, M Tian, P Chen - Int. j. morphol, 2023 - intjmorphol.com
We investigated the expression and clinical significance of miR-15b-5p in clear cell renal
cell carcinoma (RCC) through bioinformatics analysis and experimental verification. The …

Computed tomography-guided percutaneous biopsy in diagnosis of suspected metastatic renal cell carcinoma: which location is the most suitable?

P Hoffmann, M Balik, M Hoffmannova… - … i Inne Techniki …, 2024 - search.ebscohost.com
INTRODUCTION Systemic targeted therapy options are commonly used in patients with
metastatic renal cell carcinoma (mRCC). Histological verification is crucial for treatment of …